War on cancer intensifies
The pipeline for new medicines that treat cancer is stronger than ever, according to a new survey conducted by the Pharmaceutical Research and Manufacturers of America.
The pipeline for new medicines that treat cancer is stronger than ever, according to a new survey conducted by the Pharmaceutical Research and Manufacturers of America.
Pharmaceutical companies have a record 316 new cancer medicines in clinical trials or awaiting approval by the Food and Drug Administration. That number rose from 215 reported in 1995.
Potential treatments include chemotherapy drugs and medicines that fight the side effects of chemotherapy, as well as new products that may kill cancer. Medicines in development include gene therapies, monoclonal antibodies that zero in on cancer cells, light-activated medicines that attack tumor sites and vaccines that aid the body's natural cancer-fighting forces.
The 316 medicines target the three leading cancer killers -lung, breast and colon - as well as all other major sites. There are 42 drugs in development for lung cancer, 59 for breast cancer and 35 for colon cancer.
The cancer with the most drugs in development is skin cancer, which has 60 new medicines or vaccines in the pipeline. The cancer with the fewest drugs in development is Neuroblastoma, which has five.
Alan Holmer, president of PhRMA, said "The record number of medicines in development for cancer shows the commitment of the pharmaceutical industry to finding a cure for this terrible disease." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
